Lantern Pharma $LTRN: 47% R&D Cost Reduction and FDA Regulatory Progress Signal Capital-Efficient Execution in Q1 2026 @LanternPharma reported Q1 2026 results defined by measurable operating discipline — R&D spend down 47% year-over-year — while simultaneously advancing multiple clinical and technological programs through substantive milestones. Q1 Takeaways Include: • HARMONIC™ protocol now FDA-aligned: Protocol amendments targeting the L858R mutation subgroup are designed to sharpen enrollment efficiency and strength • Starlight IND cleared: Pediatric CNS cancer program advances with potential PRV eligibility intact — a voucher that has traded at $100M+ in prior transactions • Balance sheet reinforced: Up to $9.25M in new financing extends runway and supports both clinical and AI commercialization strategies • commercially live: Multi-agentic AI co-scientist platform now available via subscription, adding a potential revenue layer to complement the clinical pipeline For investors tracking clinical-stage oncology names with AI infrastructure upside, the Q1 execution print gives $LTRN a stronger story heading into the second half of 2026. Read the full Q1 2026 results: $LTRN $SXTP $INAB $DMAC $BIVI $BFRG $NSRX $CLDI $NXL $GTBP $KYNB $ANIX